ARCA Net Working Capital from 2010 to 2024

ABIO Stock  USD 3.25  0.04  1.25%   
ARCA Biopharma Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 31.4 M. During the period from 2010 to 2024, ARCA Biopharma Net Working Capital quarterly data regression pattern had sample variance of 261 T and median of  10,229,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
37 M
Current Value
31.4 M
Quarterly Volatility
16.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ARCA Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARCA main balance sheet or income statement drivers, such as Depreciation And Amortization of 105.5 K, Interest Expense of 637.9 K or Selling General Administrative of 7.2 M, as well as many exotic indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.63. ARCA financial statements analysis is a perfect complement when working with ARCA Biopharma Valuation or Volatility modules.
  
This module can also supplement ARCA Biopharma's financial leverage analysis and stock options assessment as well as various ARCA Biopharma Technical models . Check out the analysis of ARCA Biopharma Correlation against competitors.
To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

Latest ARCA Biopharma's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of ARCA Biopharma over the last few years. It is ARCA Biopharma's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARCA Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

ARCA Net Working Capital Regression Statistics

Arithmetic Mean20,177,496
Geometric Mean15,348,442
Coefficient Of Variation80.06
Mean Deviation14,187,328
Median10,229,000
Standard Deviation16,154,554
Sample Variance261T
Range44.9M
R-Value0.72
Mean Square Error135.8T
R-Squared0.52
Significance0
Slope2,596,404
Total Sum of Squares3653.6T

ARCA Net Working Capital History

202431.4 M
202337 M
202241.6 M
202150.9 M
202046.5 M
20197.6 M
2018M

About ARCA Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ARCA Biopharma income statement, its balance sheet, and the statement of cash flows. ARCA Biopharma investors use historical funamental indicators, such as ARCA Biopharma's Net Working Capital, to determine how well the company is positioned to perform in the future. Although ARCA Biopharma investors may use each financial statement separately, they are all related. The changes in ARCA Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ARCA Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ARCA Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ARCA Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital37 M31.4 M

Pair Trading with ARCA Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against ARCA Stock

  0.85JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.68PFE Pfizer Inc Sell-off TrendPairCorr
  0.48KZR Kezar Life Sciences Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock:
Check out the analysis of ARCA Biopharma Correlation against competitors.
To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for ARCA Stock analysis

When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(0.11)
Return On Equity
(0.14)
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.